0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Anti-TNF agents for rheumatoid arthritis : Anti-TNF agents for rheumatoid arthritis

      , , ,
      British Journal of Clinical Pharmacology
      Wiley

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

          We evaluated the safety and efficacy of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid arthritis who did not tolerate or had an inadequate response to methotrexate. Patients 4 to 17 years old received 0.4 mg of etanercept per kilogram of body weight subcutaneously twice weekly for up to three months in the initial, open-label part of a multicenter trial. Those who responded to treatment then entered a double-blind study and were randomly assigned to receive either placebo or etanercept for four months or until a flare of the disease occurred. A response was defined as an improvement of 30 percent or more in at least three of six indicators of disease activity, with no more than one indicator worsening by more than 30 percent. At the end of the open-label study, 51 of the 69 patients (74 percent) had had responses to etanercept treatment. In the double-blind study, 21 of the 26 patients who received placebo (81 percent) withdrew because of disease flare, as compared with 7 of the 25 patients who received etanercept (28 percent) (P=0.003). The median time to disease flare with placebo was 28 days, as compared with more than 116 days with etanercept (P<0.001). In the double-blind study, there were no significant differences between the two treatment groups in the frequency of adverse events. Treatment with etanercept leads to significant improvement in patients with active polyarticular juvenile rheumatoid arthritis. Etanercept is well tolerated by pediatric patients.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

                Bookmark

                Author and article information

                Journal
                British Journal of Clinical Pharmacology
                Wiley
                03065251
                13652125
                March 2001
                July 07 2008
                : 51
                : 3
                : 201-208
                Article
                10.1046/j.1365-2125.2001.00321.x
                2015031
                11298065
                a1343f98-7c92-4468-bea3-a69f9d6bd80d
                © 2008

                http://doi.wiley.com/10.1002/tdm_license_1.1

                History

                Comments

                Comment on this article